Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)

AstraZeneca

Status: Completed

Conditions: Diabetes; Dyslipidemia

Study type: Observational

Funder types: Industry

Identifiers

NCT00526552

NIS-CKR-CRE-2007/3

Details and patient eligibility

About

To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with diabetes

Enrollment: 5,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria

  1. Over 18 years of age
  2. Diagnosed with DM based on fasting or post-load glucose data and/or clinical assessment by the clinician

Exclusion criteria

1. Patients already taking other hyperlipidemic agents
2. Patients who do not fulfil the indication criteria for statin therapy
3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data